18 completed, 9 recruiting, 5 terminated, 3 active not recruiting. 40 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 40 | Completed 18, Recruiting 9, Terminated 5, Active not recruiting 3, Not yet recruiting 3, Unknown 2 |
| Phase 1 | 4 | Completed 2, Recruiting 2 |
| Phase 3 | 1 | Completed 1 |
Follow Adrenocortical Hyperfunction: new trials by email Literature Review of Adrenocortical Hyperfunction trials Research Report on Adrenocortical Hyperfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS Metyrapone 250 mg Oral Tablets, Placebo - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | Phase 2 | Recruiting | Mayo Clinic | 90 | 2026-10-01 | 2026-09-25 |
| A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism SAL0140 Tablets, SAL0140 placebo - Primary Aldosteronism | Phase 2 | Not yet recruiting | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 50 | 2026-06-12 | 2026-06-12 |
| Study of QLS1410 in the Treatment of Primary Aldosteronism. QLS1410, Placebo - Primary Aldosteronism | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 60 | 2026-06-01 | 2026-04-24 |
| A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism HRS-1780 Tablets, Placebo - Primary Aldosteronism | Phase 2 | Active not recruiting | Shandong Suncadia Medicine Co., Ltd. | 61 | 2026-04-23 | 2026-10-13 |
| Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) Osilodrostat 1 MG - Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS) | Phase 2 | Recruiting | Mayo Clinic | 15 | 2026-01-14 | 2026-02-11 |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) clofutriben, Placebo - Type 2 Diabetes, Cortisol Excess | Phase 2 | Recruiting | Sparrow Pharmaceuticals | 1500 | 2025-11-29 | 2026-10-06 |
| Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome Desmopressin, Dexamethasone - Cushing Syndrome | Phase 2 | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 140 | 2024-12-12 | 2026-08-31 |
| Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate [18F]CETO tracer, Dexamethasone oral, Adrenal vein sampling - Primary Aldosteronism | Phase 1 / Phase 2 | Recruiting | University Medical Center Groningen | 12 | 2024-11-06 | 2025-01-27 |
| Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism [68Ga]Ga-PentixaFor - Hyperaldosteronism, Hypercortisolism | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2024-09-23 | 2026-10-22 |
| Evaluation of [68Ga]Ga-PentixaFor PET Imaging for the Identification of Unilateral Adrenal Secretion of ALdosterON in Patients With Primary Aldosteronism [68Ga]Ga-PentixaFor PET imaging - Primary Aldosteronism | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 20 | 2024-06-01 | 2024-06-27 |
| Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism Al18F-NOTA-Pentixafor PET/CT - Primary Aldosteronism, Primary Aldosteronism Due to Aldosterone Producing Adenoma | Phase 1 / Phase 2 | Recruiting | Peking Union Medical College Hospital | 150 | 2023-12-30 | 2025-02-26 |
| Metyrapone for Mild Autonomous Cortisol Secretion (MACS) Metyrapone - Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS) | Phase 2 | Active not recruiting | Mayo Clinic | 30 | 2023-12-19 | 2026-09-25 |
| A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome atumelnant - Cushing Syndrome, Cushing Disease | Phase 1 / Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 19 | 2023-10-12 | 2026-10-14 |
| Nuclear Imaging for Subtype Diagnosis of Primary Aldosteronism [18-F]CETO - Primary Aldosteronism | Phase 2 | Unknown | University of Calgary | 30 | 2023-01-01 | 2024-07-24 |
| SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome SPI-62, Placebo - Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion | Phase 2 | Completed | Sparrow Pharmaceuticals | 26 | 2022-09-01 | 2025-10-08 |
| Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome LCI699 - Cushing Syndrome | Phase 2 | Recruiting | RECORDATI GROUP | 12 | 2021-04-28 | 2026-03-27 |
| A Study of CIN-107 in Adults With Primary Aldosteronism CIN-107 2 mg dosing, CIN-107 4 mg dosing, CIN-107 8 mg dosing - Primary Aldosteronism, Hyperaldosteronism | Phase 2 | Completed | AstraZeneca | 15 | 2021-03-08 | 2026-03-03 |
| Calcium Channel Blockade in Primary Aldosteronism Amlodipine - Primary Aldosteronism, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral) | Phase 2 | Completed | Brigham and Women's Hospital | 15 | 2020-09-01 | 2025-04-15 |
| 11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours 11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre - Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism | Phase 2 / Phase 3 | Completed | Changi General Hospital | 97 | 2019-12-30 | 2026-10-26 |
| DP13 - A Phase II Study in Patients With Primary Aldosteronism dexfadrostat phosphate - Primary Aldosteronism | Phase 2 | Completed | Damian Pharma AG | 35 | 2019-11-21 | 2024-11-22 |
Showing 20 of 40. Sign in to see all of them.
Cushing Syndrome (22) · Hyperaldosteronism (16) · ACTH Syndrome, Ectopic (10) · Pituitary ACTH Hypersecretion (6) · Hypertension (5) · Adrenal Cortex Neoplasms (3) · Adrenal Hyperplasia, Congenital (3) · Adrenocortical Carcinoma (3) · Diabetes Mellitus, Type 2 (3) · Adrenal Gland Neoplasms (2) · Diabetes Mellitus (2) · Endocrine System Diseases (2) · Pituitary Diseases (2) · Acth-Independent Macronodular Adrenal Hyperplasia (1)
Adrenal Gland Diseases (40) · Endocrine System Diseases (38) · Neoplasms (16) · Paraneoplastic Endocrine Syndromes (10) · Paraneoplastic Syndromes (10) · Metabolic Diseases (9) · Nutritional and Metabolic Diseases (9) · Neoplasms by Site (8) · Brain Diseases (7) · Central Nervous System Diseases (7) · Endocrine Gland Neoplasms (7) · Hypothalamic Diseases (7) · Nervous System Diseases (7) · Cardiovascular Diseases (6)
Osilodrostat (6) · Dexamethasone (3) · Abiraterone Acetate (2) · Amlodipine (2) · Metyrapone (2) · Mifepristone (2) · fluorodopa F 18 (2) · relacorilant (2) · ASP3662 (1) · Adrenalectomy (1) · Cabergoline (1) · Deamino Arginine Vasopressin (1) · Eplerenone (1) · Everolimus (1) · Fluorodeoxyglucose F18 (1)
Novartis Pharmaceuticals (4) · Mayo Clinic (3) · Corcept Therapeutics (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · National Cancer Institute (NCI) (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · RECORDATI GROUP (2) · Sparrow Pharmaceuticals (2) · Andrea M. Isidori (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · Brigham and Women's Hospital (1) · Changi General Hospital (1) · Crinetics Pharmaceuticals Inc. (1)
United States (25) · Italy (10) · France (7) · Netherlands (6) · Germany (5) · Belgium (4) · China (4) · United Kingdom (4) · Bulgaria (3) · Canada (3) · Hungary (3) · Japan (3) · Spain (3) · Argentina (2) · Austria (2)
Lynnette K Nieman, M.D. (5) · Irina Bancos, MD (2) · Alexander Leung, MD (1) · Anand Vaidya, MD (1) · Andreas G Moraitis, MD (1) · Dhaval T Patel, M.D. (1) · Dr. M.N. Kerstens (1) · Elisa Giannetta, MD - Phd (1) · Frank Czerwiec, MD (1) · Irina Bancos, MD, MS (1) · James Findling, MD (1) · John McNally (1) · Marc Y Donath, Prof. (1)
PMID 11745214, PMID 14985252, PMID 16172198, PMID 16580903, PMID 16670169, PMID 18619560, PMID 18957506, PMID 19223900, PMID 19500762, PMID 20837883, PMID 21220434, PMID 21612468, PMID 22997446, PMID 23470964, PMID 24107737, PMID 24210085, PMID 24268504, PMID 24423285, PMID 24482099, PMID 25968622, PMID 26353009, PMID 31246234, PMID 32923850, PMID 33507248, PMID 33794293, PMID 33859526, PMID 34335465, PMID 35058882, PMID 36074157, PMID 37490693, PMID 37876540, PMID 41052284, PMID 42535456
2023 (2), 2015 (1), 2016 (1), 2018 (1), R21DK103198 (1), ZIADK075121 (1)